Q1FY26 revenues at ?12.7 billion, YoY growth of 142% and flat QoQ growth. This includes revenues from the acquired NRT business.

Dr Reddy's Laboratories received a Form 483 with seven observations from the USFDA for its Srikakulam-based plant in Andhra ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in approval for deramiocel. Read more on CAPR stock here.

Emcure Pharma gets two observations for API plant from USFDA “We are addressing the observations comprehensively,” the company said.

USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of ...

On Friday, BTIG reaffirmed its Buy rating and $10.00 stock price target for Humacyte (NASDAQ:HUMA) following the release of a Form 483 from the FDA.

From truckloads of torn documents to avian incursions in the production plant, Granules India’s recent manufacturing reprimand from the FDA is alarming no matter which way you look at it ...

API manufacturer Global Calcium has been struck with a Form 483 filing following an FDA inspection of its factory in India. Between 29 July and 2 August 2024, the agency inspected Global Calcium ...

API manufacturer Global Calcium has been struck with a Form 483 filing following an FDA inspection of its factory in India.

Gland Pharma's Hyderabad facility gets 3 form 483 observations from USFDA This is the second surprise inspection the USFDA has carried out in a week.